Correlation of p63 Protein Expression With Histological Grade of Meningiomas

Mittal, Suchi; Jain, Deepali; Roy, S. C. Dutta; Mehta, Veer Singh

doi:10.1177/1066896911434549

Cited by 8 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This arachnoid sample also had some Cyclin D1 positive cap cells, but it is not clear if this deceased patient was developing meningioma. Mittal and coworkers [ 59 ] demonstrated by IHC positive nuclear p63 staining in meningioma that it increased with higher grades (II and III). More arachnoid autopsies should be analyzed in order to elaborate on the significance of p63 expression in the cap cells, as well as its potential significance in meningioma.…”

Section: Discussionmentioning

confidence: 99%

Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors

El-Gewely

Andreassen

Walquist

et al. 2016

Cancers

View full text Add to dashboard Cite

Meningiomas represent the most common primary tumors of the central nervous system, but few microRNA (miRNA) profiling studies have been reported so far. Deep sequencing of small RNA libraries generated from two human meningioma biopsies WHO grades I (benign) and II (atypical) were compared to excess dura controls. Nineteen differentially expressed miRNAs were validated by RT-qPCR using tumor RNA from 15 patients and 5 meninges controls. Tumor suppressor miR-218 and miR-34a were upregulated relative to normal controls, however, miR-143, miR-193b, miR-451 and oncogenic miR-21 were all downregulated. From 10 selected putative mRNA targets tested by RT-qPCR only four were differentially expressed relative to normal controls. PTEN and E-cadherin (CDH1) were upregulated, but RUNX1T1 was downregulated. Proliferation biomarker p63 was upregulated with nuclear localization, but not detected in most normal arachnoid tissues. Immunoreactivity of E-cadherin was detected in the outermost layer of normal arachnoids, but was expressed throughout the tumors. Nuclear Cyclin D1 expression was positive in all studied meningiomas, while its expression in arachnoid was limited to a few trabecular cells. Meningiomas of grades I and II appear to share biomarkers with malignant tumors, but with some additional tumor suppressor biomarkers expression. Validation in more patients is of importance.

show abstract

Section: Discussionmentioning

confidence: 99%

Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors

El-Gewely

Andreassen

Walquist

et al. 2016

Cancers

View full text Add to dashboard Cite

show abstract

“…[ 5 , 18 , 19 ] In this study; however, a significant percentage of the WHO grade 1 tumors showed immunopositivity (27.6%) similar to the report by Mittal et al . [ 20 ] in India where their study showed 34.9% immunopositivity in the WHO grade 1 tumors thus concluding that it cannot be used as a sole marker in grading meningiomas.…”

Section: Discussionmentioning

confidence: 99%

Correlation of progesterone receptors and P63 to the histological grade of meningiomas: Review and significance in an African population

Eluke,

Aniume,

Olusina

et al. 2023

JNRP

View full text Add to dashboard Cite

Objectives: Meningiomas, a common neoplasm of the central nervous system, is a widely studied meningeal tumor. According to the World Health Organization (WHO) 2021 classification of meningiomas, there are 15 subtypes that have been grouped into grades 1, 2, and 3. The WHO grade 1 meningiomas are generally grouped as benign while the WHO grades 2 and 3 tumors are grouped as malignant. Progesterone receptors and P63 are common immunohistochemical markers that have proven useful in the diagnosis, grading, and prognostication of many neoplasms such as breast carcinoma, prostate carcinoma, and gastrointestinal tumors in histopathology practice. The application of these immunohistochemical markers to the grading of meningiomas has been reported and their usefulness documented in reports from Africa, Europe, North America, South America, and Asia. This study, therefore, seeks to determine if these findings are applicable to the meningiomas seen in an African population. Materials and Methods: A 10-year review of results and histologically diagnosed cases of meningiomas received in the Department of Morbid Anatomy, University of Nigeria, Enugu. Immunostaining for progesterone receptors (PgRs) and P63 were done and results compared with histologic grades. Results: The three WHO grades of meningioma were assessed in this study. M: F ratio was 1:1.4 and peak age was 41–50 years age range (SD ± 16.54). The majority of the cases were WHO grade 1 (86.1%) while the WHO grades 2 and 3 tumors were 8% and 5.9%, respectively. The fibrous variant was the most common subtype (27.1%). There was no correlation between progesterone receptor and P63 immunopositivity to the WHO grades of meningioma (P = 0.112 and P = 0.138, respectively). Conclusion: Our study showed that progesterone receptors and P63 immunopositivity did not correlate with the WHO grades of meningiomas. This may be due to the predominant variant of meningioma seen in this study. These findings indicate that PgR antagonist may not be an effective alternative for treatment in patients with inoperable meningiomas. Furthermore, P63 immunopositivity may not be a sufficient grading tool for managing meningiomas in our population.

show abstract

“…7 -17 Interestingly, p63 expression has recently been described in cranial-based meningiomas, and immunohistochemical studies indicate that there could be a correlation between the degree of p63 expression and histological tumor grade. 6,18 To our knowledge, there are no previously published articles describing the staining pattern of p63 in cutaneous meningioma.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous meningioma: a potential diagnostic pitfall in p63 positive cutaneous neoplasms

Fox

Billings

Gleason³

et al. 2013

J Cutan Pathol

View full text Add to dashboard Cite

Cutaneous meningiomas are divided into three groups. Type I lesions present at birth and are derived from ectopic arachnoid cells. Type II lesions usually present in adults and are derived from arachnoid cells surrounding nerve bundles. Type III lesions are due to direct extension or metastasis from dural-based neoplasms. Dural-based meningiomas are known to express p63. The aim of our study is to examine the expression of p63 in type II and type III meningioma. Two cases of cutaneous meningioma (type II and type III) were evaluated for the expression of p63, EMA, CK 5/6, S100 and CD31. The cells of interest were spindled to epithelioid and arranged in a whorling pattern. Immunohistochemical staining showed expression of EMA and p63 in both cases, while stains for CK 5/6, S100 and CD31 were negative. Among cutaneous tumors, p63 is considered a marker of epithelial derivation, as it is positive in epidermal and adnexal neoplasms. It is important to be aware of p63 expression in the context of cutaneous meningioma to avoid misinterpretation as an epithelial tumor. On the basis of our small study, it is unlikely that p63 expression would be helpful in distinguishing between type II and type III meningioma, as both may be p63-positive.

show abstract

Correlation of p63 Protein Expression With Histological Grade of Meningiomas

Cited by 8 publications

References 18 publications

Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors

Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors

Correlation of progesterone receptors and P63 to the histological grade of meningiomas: Review and significance in an African population

Cutaneous meningioma: a potential diagnostic pitfall in p63 positive cutaneous neoplasms

Contact Info

Product

Resources

About